However, SCFAs can mitigate the T2DM-associated biological disruptions as they have demonstrated functional interactions with other endocrine hormones, such as leptin, ghrelin, peptide YY, and GLP-1. Here, GLP1R is linked to type 2 diabetes mellitus.